α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects

Molecular Neurobiology

Volumn 55, Issue 3, 2018, Pages 2653-2675

  Daniele, Simona ^a   Pietrobono, Deborah ^a   Fusi, Jonathan ^a   Iofrida, Caterina ^a   Chico, Lucia ^a   Petrozzi, Lucia ^a   Gerfo, Annalisa Lo ^a   Baldacci, Filippo ^a   Galetta, Fabio ^a   Siciliano, Gabriele ^a   Bonuccelli, Ubaldo ^a   Santoro, Gino ^a   Trincavelli, Maria Letizia ^a   Franzoni, Ferdinando ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Antioxidant capability; Neurodegenerative diseases; Physical exercise; Protein misfolding; Tau; Synuclein; Synuclein heterocomplexes; Amyloid

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTIOXIDANT; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PROTEIN AGGREGATE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; ERYTHROCYTE; HUMAN; HUMAN CELL; NORMAL HUMAN; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN MISFOLDING; BLOOD; ENDURANCE; EXERCISE; FEMALE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; BIOMARKERS; COHORT STUDIES; ERYTHROCYTES; EXERCISE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PHYSICAL ENDURANCE; PROTEIN AGGREGATES; TAU PROTEINS; YOUNG ADULT;

EID: 85017589309     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-017-0523-5     Document Type: Article

References (98)

1. Kim GH, Kim JE, Rhie SJ, Yoon S (2015) The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol 24:325–340
2. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795
3. Gandhi S, Abramov AY (2012) Mechanism of oxidative stress in neurodegeneration. Oxidative Med Cell Longev. doi:10.1155/2012/428010
4. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A (2006) Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med 10:389–406
5. Klein WL, Stine WB, Teplow DB (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25:569–580
6. Ugalde CL, Finkelstein DI, Lawson VA, Hill AF (2016) Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers. J Neurochem 139:162–180
7. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9:13–24
8. Maurer K, Volk S, Gerbaldo H (1997) Auguste D and Alzheimer's disease. Lancet 349:1546–1549
9. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. doi:10.1101/cshperspect.a006189
10. Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, Lesné SE (2012) Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci 32:10253–10266
11. Marsh SE, Blurton-Jones M (2012) Examining the mechanisms that link β-amyloid and α-synuclein pathologies. Alzheimers Res Ther 4:11
12. Trojanowski JQ (2002) Emerging Alzheimer's disease therapies: focusing on the future. Neurobiol Aging 23:985–990
13. Lee VM, Giasson BI, Trojanowski JQ (2004) More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Trends Neurosci 27:129–134
14. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R (2006) Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 31:1153–1162
15. Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E et al (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One. doi:10.1371/journal.pone.0003135
16. Benussi L, Ghidoni R, Paterlini A, Nicosia F, Alberici AC, Signorini S, Barbiero L, Binetti G (2005) Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. Exp Cell Res 308:78–84
17. Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Gonçalves SA, Pera M, Suárez-Calvet M, Clarimon J et al (2011) Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One. doi:10.1371/journal.pone.0026609
18. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636–640
19. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R (1999) Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 274:25481–25489
20. Growdon JH (1999) Biomarkers of Alzheimer disease. Arch Neurol 56:281–283
21. Garlind A, Brauner A, Höjeberg B, Basun H, Schultzberg M (1999) Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res 826:112–116
22. Hock C, Heese K, Müller-Spahn F, Huber P, Riesen W, Nitsch RM, Otten U (2000) Increased CSF levels of nerve growth factor in patients with Alzheimer's disease. Neurology 54:2009–2011
23. Hampel H, Buerger K, Kohnken R, Teipel SJ, Zinkowski R, Moeller HJ, Rapoport SI, Davies P (2001) Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 49:545–546
24. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58:373–379
25. Reiber H (2003) Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 21:79–96
26. Chen X, Guo C, Kong J (2012) Oxidative stress in neurodegenerative diseases. Neural Regen Res 7:376–385
27. Williams A (2002) Defining neurodegenerative diseases. BMJ 324:1465–1466
28. Patten DA, Germain M, Kelly MA, Slack RS (2010) Reactive oxygen species: stuck in the middle of neurodegeneration. J Alzheimers Dis 20(Suppl 2):S357–S367
29. Ienco EC, LoGerfo A, Carlesi C, Orsucci D, Ricci G, Mancuso M, Siciliano G (2011) Oxidative stress treatment for clinical trials in neurodegenerative diseases. J Alzheimers Dis 24(Suppl 2):111–126
30. Navarro A, Boveris A (2010) Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease. Front Aging Neurosci. doi:10.3389/fnagi.2010.00034
31. Fulda S, Gorman AM, Hori O, Samali A (2010) Cellular stress responses: cell survival and cell death. Int J Cell Biol. doi:10.1155/2010/214074
32. Halliwell B (1994) Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344:721–724
33. Feng Y, Wang X (2012) Antioxidant therapies for Alzheimer's disease. Oxidative Med Cell Longev. doi:10.1155/2012/472932
34. Singh S (2015) Antioxidants as a preventive therapeutic option for age related neurodegenerative diseases. Ther Targets Neurol Dis. doi:10.14800/ttnd.592
35. Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nat Rev Neurosci 7:278–294
36. Radak Z, Suzuki K, Higuchi M, Balogh L, Boldogh I, Koltai E (2016) Physical exercise, reactive oxygen species and neuroprotection. Free Radic Biol Med 98:187–196
37. Voss MW, Vivar C, Kramer AF, van Praag H (2013) Bridging animal and human models of exercise-induced brain plasticity. Trends Cogn Sci 17:525–544
38. Power GA, Dalton BH, Rice CL (2013) Human neuromuscular structure and function in old age: a brief review. J Sport Health Sci 2:215–226
39. Johnson RA, Mitchell GS (2003) Exercise-induced changes in hippocampal brain-derived neurotrophic factor and neurotrophin-3: effects of rat strain. Brain Res 983:108–114
40. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM et al (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120:701–713
41. Tapia-Rojas C, Aranguiz F, Varela-Nallar L, Inestrosa NC (2016) Voluntary running attenuates memory loss, decreases neuropathological changes and induces neurogenesis in a mouse model of Alzheimer's disease. Brain Pathol 26:62–74
42. Brown BM, Peiffer JJ, Taddei K, Lui JK, Laws SM, Gupta VB et al (2013) Physical activity and amyloid-β plasma and brain levels: results from the Australian imaging, biomarkers and lifestyle study of ageing. Mol Psychiatry 18:875–881
43. Ang ET, Tai YK, Lo SQ, Seet R, Soong TW (2010) Neurodegenerative diseases: exercising toward neurogenesis and neuroregeneration. Front Aging Neurosci. doi:10.3389/fnagi.2010.00025
44. Pandey KB, Rizvi SI (2010) Markers of oxidative stress in erythrocytes and plasma during aging in humans. Oxidative Med Cell Longev 3:2–12
45. Wang X, Yu S, Li F, Feng T (2015) Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. Neurosci Lett 599:115–119
46. Kiko T, Nakagawa K, Satoh A, Tsuduki T, Furukawa K, Arai H et al (2012) Amyloid β levels in human red blood cells. PLoS One. doi:10.1371/journal.pone.0049620
47. Whaley MH, Brubaker PH, Otto RM, Armstrong LE (2006) Medicine ACoS Guidelines for exercise testing and prescription, 7th edn. Lippincott Williams & Wilkins, Philadelphia
48. Borg GA (1982) Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14:377–381
49. Hamer P, Slocombe B (1997) The psychophysical and heart rate relationship between treadmill and deep-water running. Aust J Physiother 43:265–271
50. Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F et al (2013) Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One. doi:10.1371/journal.pone.0072281
51. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P et al (2011) Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 25:4127–4137
52. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA et al (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 20:419–425
53. Pesini P, Pérez-Grijalba V, Monleón I, Boada M, Tárraga L, Martínez-Lage P et al (2012) Reliable measurements of the β-amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimers Dis. doi:10.1155/2012/604141
54. Zappelli E, Daniele S, Abbracchio MP, Martini C, Trincavelli ML (2014) A rapid and efficient immunoenzymatic assay to detect receptor protein interactions: G protein-coupled receptors. Int J Mol Sci 15:6252–6264
55. Daniele S, Taliani S, Da Pozzo E, Giacomelli C, Costa B, Trincavelli ML et al (2014) Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci Rep 4:4749
56. Winston GW, Regoli F, Dugas AJ, Fong JH, Blanchard KA (1998) A rapid gas chromatographic assay for determining oxyradical scavenging capacity of antioxidants and biological fluids. Free Radic Biol Med 24:480–493
57. Regoli F, Winston GW (1999) Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals. Toxicol Appl Pharmacol 156:96–105
58. Franzoni F, Ghiadoni L, Galetta F, Plantinga Y, Lubrano V, Huang Y et al (2005) Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens 18:510–516
59. Bianchi S, Fusi J, Franzoni F, Giovannini L, Galetta F, Mannari C et al (2016) Effects of recombinant human erythropoietin high mimicking abuse doses on oxidative stress processes in rats. Biomed Pharmacother 82:355–363
60. Franzoni F, Colognato R, Galetta F, Laurenza I, Barsotti M, Di Stefano R et al (2006) An in vitro study on the free radical scavenging capacity of ergothioneine: comparison with reduced glutathione, uric acid and trolox. Biomed Pharmacother 60:453–457
61. Bartels T, Choi J, Kim N, Selkoe D (2011) Non-denaturing purification of alpha-Synuclein from erythrocytes. Protoc Exch. doi:10.1038/protex.2011.254
62. Nielsen H, Ek D, Avdic U, Orbjörn C, Hansson O, Veerhuis R et al (2013) NG2 cells, a new trail for Alzheimer's disease mechanisms? Acta Neuropathol Commun. doi:10.1186/2051-5960-1-7
63. Cerf E, Sarroukh R, Tamamizu-Kato S, Breydo L, Derclaye S, Dufrêne YF et al (2009) Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide. Biochem J 421:415–423
64. Kostylev MA, Kaufman AC, Nygaard HB, Patel P, Haas LT, Gunther EC et al (2015) Prion-protein-interacting amyloid-β oligomers of high molecular weight are tightly correlated with memory impairment in multiple Alzheimer mouse models. J Biol Chem 290:17415–17438
65. Jimenez S, Navarro V, Moyano J, Sanchez-Mico M, Torres M, Davila JC et al (2014) Disruption of amyloid plaques integrity affects the soluble oligomers content from Alzheimer disease brains. PLoS One 9(12):e114041
66. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L et al (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5:55–59
67. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33:95–130
68. Santpere G, Puig B, Ferrer I (2006) Low molecular weight species of tau in Alzheimer's disease are dependent on tau phosphorylation sites but not on delayed post-mortem delay in tissue processing. Neurosci Lett 399:106–110
69. Goraca A (2004) Assessment of total antioxidant capacity in human plasma. Folia Med (Plovdiv) 46:16–21
70. Dose J, Huebbe P, Nebel A, Rimbach G (2016) APOE genotype and stress response—a mini review. Lipids Health Dis 15:121
71. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31:1275–1283
72. Head D, Bugg JM, Goate AM, Fagan AM, Mintun MA, Benzinger T et al (2012) Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. Arch Neurol 69:636–643
73. Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer's disease. Oxidative Med Cell Longev. doi:10.1155/2013/316523
74. Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson's disease. Front Neuroanat 9:91
75. Danev SI, St Stoyanov D (2010) Early noninvasive diagnosis of neurodegenerative diseases. Folia Med (Plovdiv) 52:5–13
76. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M et al (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30:1026–1036
77. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J et al (2004) Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol 44:854–860
78. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ et al (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949–953
79. Ridley RM, Baker HF, Windle CP, Cummings RM (2006) Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm (Vienna) 113:1243–1251
80. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372–381
81. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstermacher JD (1996) Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67:880–883
82. Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89:807–811
83. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H et al (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330:980–982
84. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98:8850–8855
85. Mohanty JG, Nagababu E, Rifkind JM (2014) Red blood cell oxidative stress impairs oxygen delivery and induces red blood cell aging. Front Physiol 5:84
86. Radak Z, Hart N, Sarga L, Koltai E, Atalay M, Ohno H et al (2010) Exercise plays a preventive role against Alzheimer's disease. J Alzheimers Dis 20:777–783
87. Inal ME, Kanbak G, Sunal E (2001) Antioxidant enzyme activities and malondialdehyde levels related to aging. Clin Chim Acta 305:75–80
88. Tuon T, Valvassori SS, Lopes-Borges J, Luciano T, Trom CB, Silva LA et al (2012) Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson's disease. Neuroscience 227:305–312
89. Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM et al (2010) Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 68:311–318
90. Sparks DL, Kryscio RJ, Sabbagh MN, Ziolkowski C, Lin Y, Sparks LM et al (2012) Tau is reduced in AD plasma and validation of employed ELISA methods. Am J Neurodegener Dis 1:99–106
91. Ohia-Nwoko O, Montazari S, Lau YS, Eriksen JL (2014) Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. Mol Neurodegener 9:54
92. Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 273:26292–26294
93. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M et al (2001) Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98:12245–12250
94. Smith JA (1995) Exercise, training and red blood cell turnover. Sports Med 19:9–31
95. Kaestner L, Bogdanova A (2014) Regulation of red cell life-span, erythropoiesis, senescence, and clearance. Front Physiol 5:269
96. Lombardi G, Colombini A, Lanteri P, Banfi G (2013) Reticulocytes in sports medicine: an update. Adv Clin Chem 59:125–153
97. Hu M, Lin W (2012) Effects of exercise training on red blood cell production: implications for anemia. Acta Haematol 127:156–164
98. Díaz V, Lombardi G, Ricci C, Jacobs RA, Montalvo Z, Lundby C et al (2011) Reticulocyte and haemoglobin profiles in elite triathletes over four consecutive seasons. Int J Lab Hematol 33:638–644